Approval of alteplase in Europe: will it change stroke management?

Lancet Neurol. 2003 Apr;2(4):207-8. doi: 10.1016/s1474-4422(03)00343-0.

Author

Affiliation

¹ Department of Neurology, Helsinki University Central Hospital, FIN-00029 HUS, Helsinki, Finland. markku.kaste@hus.fi <markku.kaste@hus.fi>

PMID: 12849203
DOI: 10.1016/s1474-4422(03)00343-0

No abstract available

MeSH terms

Drug Approval*
Europe
Fibrinolytic Agents / therapeutic use*
Humans
Practice Patterns, Physicians'*
Stroke / drug therapy*
Tissue Plasminogen Activator / therapeutic use*

Substances

Fibrinolytic Agents
Tissue Plasminogen Activator